Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 190.52 |
| Open | 190.72 |
| Bid | 194.33 x 100 |
| Ask | 194.50 x 100 |
| Day's Range | 189.44 - 194.52 |
| 52 Week Range | 189.44 - 319.76 |
| Volume | |
| Avg. Volume | 1,179,530 |
| Market Cap | 28.255B |
| Beta (5Y Monthly) | -0.01 |
| PE Ratio (TTM) | 24.42 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
What's in Store for Biogen (BIIB) This Earnings Season?
Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been moderate.
- Zacks
Gear Up for Biogen (BIIB) Q1 Earnings: Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Biogen (BIIB), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
- Investor's Business Daily
Is Eli Lilly Stock A Buy After Weight-Loss Drug Succeeds In Sleep Apnea Patients?
Lilly is soon planning to ask global regulators to approve tirzepatide for sleep apnea treatment. Is Eli Lilly stock a buy?
© 2024 Yahoo. All rights reserved.